Immunotherapy — Safety and Efficacy of Camrelizumab for High-risk NMIBC Failing BCG Treatment
Citation(s)
A Phase I/II Single Arm Study of Intravesical Administration With Camrelizumab for High-risk Non-muscle Invasive Bladder Cancer(NMIBC) Failing in BCG Treatment